Physician profile
Ira E Stein
NPI 1790757821
$6,397.66
in general payments reported to CMS, 2019-2025
34 companies · $1,309 in 2025
The $1,309 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $423 · 2021: $1,145 · 2022: $1,257 · 2023: $839 · 2024: $1,152 · 2025: $1,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,300.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,377.00 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $705.49 | 2019-2025 | Tremfya |
| Gilead Sciences, INC. | $329.91 | 2019-2024 | Veklury |
| Boston Scientific Corporation | $236.33 | 2021-2022 | |
| Genzyme Corporation | $190.69 | 2024-2025 | |
| Qol Medical, LLC | $183.21 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $178.54 | 2020-2025 | Xifaxan |
| Pfizer INC. | $170.36 | 2019-2025 | |
| Celgene Corporation | $147.24 | 2022-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $110.99 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $74.96 | 2021-2023 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $74.76 | 2019-2025 | Entyvio |
| Nestle Healthcare Nutrition INC. | $73.79 | 2020-2023 | |
| Regeneron Healthcare Solutions, INC. | $51.75 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $50.87 | 2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $43.57 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $41.46 | 2023 | |
| Micro-Tech Endoscopy USA, INC. | $36.24 | 2024 | Guidewires |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.47 | 2024 | Cyltezo |
| Intercept Pharmaceuticals, INC. | $28.81 | 2020-2021 | |
| Redhill Biopharma INC. | $27.57 | 2020-2022 | |
| Madrigal Pharmaceuticals | $27.53 | 2024-2025 | Resmetirom, Rezdiffra |
| Cumberland Pharmaceuticals, INC. | $23.64 | 2025 | Vibativ |
| Astellas Pharma US INC | $23.58 | 2025 | Cresemba |
| Allergan, INC. | $23.47 | 2020 | |
| Aimmune Therapeutics, INC. | $21.80 | 2025 | Zenpep |
| Mauna Kea Technologies, INC. | $21.68 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $18.23 | 2025 | Iqirvo |
| Olympus America INC. | $17.97 | 2025 | Gastrointestinal Videoscope, Evis Exera III Colonovideoscope |
| Evoke Pharma, INC. | $12.84 | 2022 | |
| Bausch & Lomb Americas INC. | $12.46 | 2022 | |
| Ferring Pharmaceuticals INC. | $11.19 | 2020 | |
| Cook Medical LLC | $10.84 | 2019 | |
| Dynavax Technologies Corporation | $8.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ira Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.